The keynote address will provide evidence based information to guide clinicians in evaluation and treatment of high risk for genetic breast and gynecologic cancers. A review of BRCA gene function, incidence of genetic mutations related to BRCA and other high risk genes will be provided. The use of next gene sequencing and multi-gene panels and discussion of new genes that are high, moderate and low penetrance pathologic mutations that impact risk of developing breast/gynecologic cancers will be noted. Clinical management of carriers, of pathogenic gene variants will be reviewed with incidence of primary and secondary cancers. Impact of high risk for breast/gynecologic cancers pathologic genetic mutations on patient’s wellbeing, economics of surveillance vs. prophylactic surgery or chemo prevention will be addressed.

**Biography**

Denise Johnson Miller has completed her MD at Washington University Medical School, St. Louis Mo, General Surgery Residency at University of Illinois in Chicago, Fellowship in Tumor Immunology at University of Texas, Southwestern in Dallas, TX during her Surgical Residency and her Surgical Oncology Fellowship at City of Hope Medical Center in Duarte, CA. She was recruited to VA in Palo Alto and served as a Chief of General Surgery and Acting Chief of Surgery, she was then promoted to Assistant then Associate Professor of Surgery at Stanford University Medical School, where she served as an Advising Dean and Director of Melanoma Surgery. She is currently a Medical Director of Breast Surgical Oncology for the MSK Hackensack Meridian Health System in New Jersey and Clinical Associate Professor of Surgery Rutgers Medical Center and Clinical Professor of Surgery at Seton Hall University.

djohnsonmiller@meridianhealth.com

**Notes:**